Cannabis as a risk factor for psychosis: systematic review
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Various lines of evidence suggest an association between cannabis and psychosis. Five years ago, the only significant case-control study addressing this question was the Swedish Conscript Cohort. Within the last few years, other studies have emerged, allowing the evidence for cannabis as a risk factor to be more systematically reviewed and assessed. Using specific search criteria on Embase, PsychINFO and Medline, all studies examining cannabis as an independent risk factor for schizophrenia, psychosis or psychotic symptoms, published between January 1966 and January 2004, were examined. Additional studies were also reviewed from references found in retrieved articles, reviews, and a cited reference search (ISI-Web of Science). Studies selected for meta-analysis included: (i) case-control studies where exposure to cannabis preceded the onset of schizophrenia or schizophrenia-like psychosis and (ii) cohort studies of healthy individuals recruited before the median age of illness onset, with cannabis exposure determined prospectively and blind to eventual diagnosis. Studies of psychotic symptoms were also tabulated for further discussion. Eleven studies were identified examining the relationship between cannabis use and psychosis. Seven were included in the meta-analysis, with a derived odds ratio (fixed effects) of 2·9 (95% confidence interval = 2.4-3.6). No evidence of publication bias or heterogeneity was found. Early use of cannabis did appear to increase the risk of psychosis. For psychotic symptoms, a dose-related effect of cannabis use was seen, with vulnerable groups including individuals who used cannabis during adolescence, those who had previously experienced psychotic symptoms, and those at high genetic risk of developing schizophrenia. In conclusion, the available evidence supports the hypothesis that cannabis is an independent risk factor, both for psychosis and the development of psychotic symptoms. Addressing cannabis use, particularly in vulnerable populations, is likely to have beneficial effects on psychiatric morbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from most case-control and cross-sectional studies support an association between cannabis use and schizophrenia (4-6) and psychotic symptoms (7)(8)(9).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [6]
In the citing paper
“Capsaicin patches are proposed as second-line for peripheral neuropathic pain because of high quality of evidence, but modest effect size, training requirements, and potential safety concerns on sensation with long-term use.65”
From Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis (2015) · cites this paper as [65]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“Summary odds ratios were reported using a Forest plot, and publication bias was examined by visual inspection of Begg’s funnel plot (Begg and Mazumdar, 1994) and using Egger’s test (Egger et al., 1997).”
MethodMeta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813 · cited 1×
“Recent attempts to explain the association between drug misuse and schizophrenia have utilized the vulnerability hypothesis (Tsapakis et al., 2003), placing it within the framework of current ideas regarding the neurobiology of psychosis (Kapur, 2003).”
BackgroundCannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399 · cited 5×
“The Dunedin Birth Cohort Study (Arseneault et al., 2002) also found that, even when psychotic symptoms at age 11 years were controlled for, cannabis users by age 15 years and by age 18 years had significantly more ‘schizophrenia symptoms’ compared to controls (although data did not permit…”
BackgroundMethodResultInfluentialCannabis and schizophrenia. A longitudinal study of Swedish conscripts
Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92620-1 · Cited by 1,166 · cited 5×
“Similarly, the reanalysis of the Swedish Conscript Cohort (Zammit et al., 2002) was not included in the meta-analysis because, although the follow-up period was longer, the population size was smaller than the original study.”
BackgroundMethodResultInfluentialCannabis use and psychosis: A longitudinal population-based study
van Os, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf043 · Cited by 928
Causal association between cannabis and psychosis: examination of the evidence
Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.2.110 · Cited by 913 · cited 2×
“It is noteworthy that there have been a number of recent articles reviewing this topic (Arseneault et al., 2004; Smit et al., 2004) but no systematic reviews of the literature.”
BackgroundZammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871 · cited 7×
“Similarly, the reanalysis of the Swedish Conscript Cohort (Zammit et al., 2002) was not included in the meta-analysis because, although the follow-up period was longer, the population size was smaller than the original study.”
BackgroundMethodResultInfluentialSex Differences in the Risk of Schizophrenia: Evidence From Meta-analysis
Aleman, A., Kahn, R. S., & Selten, J.-P. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.565 · Cited by 818 · cited 1×
“Patterns of drug misuse, particularly cannabis, may help to explain the finding of an earlier age of onset of schizophrenia being observed in male compared to female patients in the published literature from the last two decades (Aleman et al., 2003).”
ResultA neurobiological basis for substance abuse comorbidity in schizophrenia
Chambers, R. A., Krystal, J. H., & Self, D. W. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01134-9 · Cited by 548
Elevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00008 · Cited by 432
Cannabis dependence and psychotic symptoms in young people
FERGUSSON, D. M., HORWOOD, L. J., & SWAIN-CAMPBELL, N. R. (2003) · Psychological Medicine · doi:10.1017/s0033291702006402 · Cited by 415
Dean, B., Sundram, S., Bradbury, R., Scarr, E., & Copolov, D. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00552-2 · Cited by 383
Degenhardt, L., Hall, W., & Lynskey, M. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961116037.x · Cited by 330 · cited 3×
“Degenhardt and colleagues found an increase in the OR when DSM-IV criteria were used for cannabis dependence (OR 10.8) compared to cannabis abuse (OR 4.64) (Degenhardt and Hall, 2001; Degenhardt et al., 2001).”
BackgroundInfluentialAmorim, P., Lecrubier, Y., Weiller, E., Hergueta, T., & Sheehan, D. (1998) · European Psychiatry · doi:10.1016/s0924-9338(97)86748-x · Cited by 318 · cited 1×
“Verdoux et al. (2003) found that the acute effects of cannabis were modified by the subject’s level of vulnerability for psychosis, as defined by the Mini-International Neuropsychiatric Interview (MINI, 4.4 version) criteria (Amorin et al., 1998).”
MethodInfluentialRates of Psychiatric Comorbidity Among U.S. Residents with Lifetime Cannabis Dependence
Agosti, V., Nunes, E., & Levin, F. (2002) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-120015873 · Cited by 307 · cited 2×
“The unadjusted odds ratios of those studies excluded were not substantively different from the pooled OR, with OR values of 2.06 (Andreasson et al., 1989), 2.86 (Hall and Degenhardt, 2000), 3.49 (Agosti et al., 2002) and 2.2 (Zammit et al., 2002).”
BackgroundInfluentialWilson, W., Mathew, R., Turkington, T., Hawk, T., Coleman, R. E., & Provenzale, J. (2000) · Journal of Addictive Diseases · doi:10.1300/j069v19n01_01 · Cited by 288 · cited 1×
“…symptoms; ***Episode(s) of frank psychosis lasting less than 1 week and spontaneously abated 17 years have a lower percentage of cortical grey matter and an increased percentage white matter compared to those who start later, which is unrelated to duration of cannabis use (Wilson et al., 2000).”
BackgroundTesting hypotheses about the relationship between cannabis use and psychosis
Degenhardt, L., Hall, W., & Lynskey, M. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00064-4 · Cited by 270 · cited 1×
“A recent study that used mathematical modelling to explore the possible effects of cannabis use and schizophrenia (Degenhardt et al., 2003) supported the possibility that cannabis precipitated psychosis in vulnerable individuals and that cannabis use is more likely among individuals with…”
BackgroundZavitsanou, K., Garrick, T., & Huang, X. F. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.005 · Cited by 268 · cited 1×
“…area 9) of subjects with schizophrenia, independent of recent cannabis ingestion (Dean et al., 2001) and increased binding of [3H]SR141716A (a synthetic cannabinoid-1 receptor antagonist) in the anterior cingulate cortex of subjects with schizophrenia compared to controls (Zavitsanou et al., 2004).”
BackgroundCannabis Use and Age at Onset of Schizophrenia
Veen, N. D., Selten, J.-P., van der Tweel, I., Feller, W. G., Hoek, H. W., & Kahn, R. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.501 · Cited by 266
Emrich, H. M., Leweke, F. M., & Schneider, U. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00426-1 · Cited by 226 · cited 1×
“Summary odds ratios were reported using a Forest plot, and publication bias was examined by visual inspection of Begg’s funnel plot (Begg and Mazumdar, 1994) and using Egger’s test (Egger et al., 1997).”
MethodCannabis, Vulnerability, and the Onset of Schizophrenia: An Epidemiological Perspective
Hambrecht, M., & Häfner, H. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00736.x · Cited by 205 · cited 1×
“The self-medication hypothesis suggests that patients with schizophrenia use drugs to alleviate antipsychotic medication side-effects or aversive symptoms, such as negative symptoms of schizophrenia, anxiety, depression, or dysphoria (Hambrecht and Hafner, 2000).”
BackgroundCannabis use and the risk of later schizophrenia: a review
Smit, F., Bolier, L., & Cuijpers, P. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00683.x · Cited by 203 · cited 1×
“It is noteworthy that there have been a number of recent articles reviewing this topic (Arseneault et al., 2004; Smit et al., 2004) but no systematic reviews of the literature.”
BackgroundAndréasson, S., Allebeck, P., Engström, A., & Rydberg, U. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91823-5 · Cited by 202
Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study
VERDOUX, H., GINDRE, C., SORBARA, F., TOURNIER, M., & SWENDSEN, J. D. (2003) · Psychological Medicine · doi:10.1017/s0033291702006384 · Cited by 194 · cited 2×
“Verdoux et al. (2003) found that the acute effects of cannabis were modified by the subject’s level of vulnerability for psychosis, as defined by the Mini-International Neuropsychiatric Interview (MINI, 4.4 version) criteria (Amorin et al., 1998).”
MethodInfluentialDEGENHARDT, L., & HALL, W. (2001) · Psychological Medicine · doi:10.1017/s0033291701003865 · Cited by 193 · cited 2×
“Degenhardt and colleagues found an increase in the OR when DSM-IV criteria were used for cannabis dependence (OR 10.8) compared to cannabis abuse (OR 4.64) (Degenhardt and Hall, 2001; Degenhardt et al., 2001).”
BackgroundInfluentialCannabis use and psychosis: A review of clinical and epidemiological evidence
Hall, W., & Degenhardt, L. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00685.x · Cited by 183 · cited 2×
“The unadjusted odds ratios of those studies excluded were not substantively different from the pooled OR, with OR values of 2.06 (Andreasson et al., 1989), 2.86 (Hall and Degenhardt, 2000), 3.49 (Agosti et al., 2002) and 2.2 (Zammit et al., 2002).”
BackgroundInfluentialEpidemiological analysis of alcohol and drug use as risk factors for psychotic experiences
TIEN, A. Y., & ANTHONY, J. C. (1990) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199008000-00001 · Cited by 175
Tsuang, M. T. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290020013003 · Cited by 161 · cited 1×
“Other studies suggest that there may be a shared aetiology for substance abuse and schizophrenia, such as common genetic factors (Tsuang et al., 1982) or dysregulation of neural circuitry mediating drug reward and reinforcement (Chambers et al., 2001).”
BackgroundSchizophrenia in users and nonusers of cannabis: A longitudinal study in Stockholm County
Andréasson, S., Allebeck, P., & Rydberg, U. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb10296.x · Cited by 155 · cited 2×
“However, the Stockholm County Cohort (Andreasson et al., 1989) was excluded on the grounds that it contained data for a subpopulation of a previously reported study.”
BackgroundInfluentialMiller, P. M., Lawrie, S. M., Hodges, A., Clafferty, R. A., Cosway, R., & Johnstone, E. C. (2001) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270170038 · Cited by 153 · cited 3×
“…study of a less heterogeneous population (people at high risk of developing schizophrenia for genetic reasons) did find cannabis to be an independent risk factor for the presence of psychotic symptoms, with a possible dose-related effect of both past and current cannabis use (Miller et al., 2001).”
BackgroundInfluentialSelf-citationPsychosis and drug dependence: results from a national survey of prisoners
Farrell, M., Boys, A., Bebbington, P., Brugha, T., Coid, J., Jenkins, R., Lewis, G., Meltzer, H., Marsden, J., Singleton, N., et al. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.5.393 · Cited by 140 · cited 2×
“The random effects pooled OR was calculated for the remaining seven studies (Andreasson et al., 1987; Rolfe et al., 1993; Grech et al., 1998; Arseneault et al., 2002; Farrell et al., 2002; van Os et al., 2002), with a derived value of 2.9 [95% confidence interval (CI) = 2.3–3.6].”
MethodInfluentialCannabis and psychotic illness
Mathers, D. C., & Ghodse, A. H. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.161.5.648 · Cited by 135
Cannabis Use is Not Associated With the Development of Psychosis in an ‘Ultra’ High-Risk Group
Phillips, L. J., Curry, C., Yung, A. R., Pan Yuen, H., Adlard, S., & Mcgorry, P. D. (2002) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2002.01089.x · Cited by 124
How does drug and alcohol misuse develop among people with psychotic illness? A literature review
Phillips, P. A., & Johnson, S. (2001) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270170044 · Cited by 109 · cited 1×
“Some authors contend that it may be due to socioeconomic and demographic factors common to both substance use and schizophrenia (Phillips and Johnson, 2001; Phillips et al., 2002).”
BackgroundIncidence of schizophrenia in south-east London between 1965 and 1997
Boydell, J., Van Os, J., Lambri, M., Castle, D., Allardyce, J., McCreadie, R. G., & Murray, R. M. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.1.45 · Cited by 104
[Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
Potvin, S., Stip, É., & Roy, J.-Y. (2003) · PubMed · Cited by 57
Human neuroimaging of acute and chronic marijuana use: implications for frontocerebellar dysfunction
Loeber, R. T., & Yurgelun-Todd, D. A. (1999) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(199907)14:5<291::aid-hup100>3.0.co;2-h · Cited by 53 · cited 1×
“A review of neuroimaging studies of the effects of cannabinoids in humans found clear similarities between functional networks impaired by cannabis use and those known to be implicated in the pathogenesis of schizophrenia (Loeber and Yurgelun-Todd, 1999).”
BackgroundPsychosis and Cannabis Abuse in the Gambia: A Case-Control Study
Rolfe, M., Tang, C., Sabally, S., Todd, J., Sam, E. B., & N'jie, A. B. H. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.6.798 · Cited by 35 · cited 1×
“The random effects pooled OR was calculated for the remaining seven studies (Andreasson et al., 1987; Rolfe et al., 1993; Grech et al., 1998; Arseneault et al., 2002; Farrell et al., 2002; van Os et al., 2002), with a derived value of 2.9 [95% confidence interval (CI) = 2.3–3.6].”
MethodInfluentialDoes dopamine sensitization underlie the association between schizophrenia and drug abuse?
Tsapakis, E.-M., Guillin, O., & Murray, R. M. (2003) · Current Opinion in Psychiatry · doi:10.1097/00001504-200304002-00008 · Cited by 21
Comparison of cannabis use in psychotic patients and controls in London and Malta
Grech, A., Takei, N., & Murray, R. M. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)88345-4 · Cited by 19 · cited 2×
“The random effects pooled OR was calculated for the remaining seven studies (Andreasson et al., 1987; Rolfe et al., 1993; Grech et al., 1998; Arseneault et al., 2002; Farrell et al., 2002; van Os et al., 2002), with a derived value of 2.9 [95% confidence interval (CI) = 2.3–3.6].”
MethodInfluentialSubstance Abuse as a Risk Factor for Schizophrenia and Related Disorders
Bowers, M. B., Boutros, N. N., D’Souza, D. C., & Madonick, S. H. (2001) · International Journal of Mental Health · doi:10.1080/00207411.2001.11449509 · Cited by 17 · cited 1×
“These include case reports of cannabis use preceding onset of schizophrenia, psychosis in community surveys of cannabis users, and observational studies of psychosis in cannabis users (Bowers et al., 2001).”
BackgroundCannabinoids & psychosis: Evidence from studies with I.V THC in schizophrenic patients and controls
D’Souza, D. C., Abi‐Saab, W., Madonick, S. H., Wray, Y., Forselius, K., Macdougall, L., Brush, L. N., Cassello, K., & Krystal, J. H. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(00)90371-2 · Cited by 17
[Cannabis use as a probable causative factor in the later development of schizophrenia].
Smit, F., Bolier, L., & Cuijpers, P. J. (2003) · PubMed · Cited by 7
Research works printed but not linked: 3
- 10.1080/j.1440-1614.2000.00736.x · doi:10.1080/j.1440-1614.2000.00736.x · Paper page
- Potvin S, 2003, Encephale, 29, 193
- Smit F, 2003, Ned Tijdschr Geneeskd, 147, 2178
Cited by
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
“Lack of long-term follow-up data, limited availability, and concerns over precipitating psychosis or schizophrenia, especially in individuals with environmental or genetic risk factors [103], restrict the use of cannabinoids to second-line therapy for patients with multiple sclerosis NP at present, and additional tria…”
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…IH -PA Author M anuscript 2004; Leweke et al., 2004; Manzanares et al., 2004; Ujike and Morita, 2004; Ashton et al., 2005; Gambi et al., 2005; Semple et al., 2005; Vinod and Hungund, 2005). a. Schizophrenia: Schizophrenia is the second most common mental disorder with a lifetime prevalence…”
BackgroundCannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., Seidman, L. J., Perkins, D., Tsuang, M., McGlashan, T., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.3 · Cited by 1,269
“Included in the list of potentialpredictorswerevariables foundtobeassociatedwithrisk of conversion to psychosis in previous studies of smaller samples, including genetic risk for schizophrenia,(8,21,22) severityofprodromalsymptoms,(11)severityofnonspecificsymptoms,(19) social and role functioning,(19,23,24) and substa…”
Background
Metadata
- Authors
- Semple, D. M., McIntosh, A. M., & Lawrie, S. M.
- Affiliations
- University of Edinburgh (GB)
- Corresponding author
- Semple, David M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-03
- Volume
- 19
- Issue
- 2
- Pages
- 187-194
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2129378060
- Cited by
- 420
- References
- 45
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 13 · 2022: 9 · 2021: 23 · 2020: 17 · 2019: 8 · 2018: 15 · 2017: 21 · 2016: 29 · 2015: 26 · 2014: 25 · 2013: 22 · 2012: 26
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychopathy, Forensic Psychiatry, Sexual Offending
- Keywords
- cannabis use, psychosis, schizophrenia, psychotic symptoms, risk factors, adolescent cannabis use, dose-response relationship, genetic risk, psychiatric morbidity
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Female, Humans, Longitudinal Studies, Male, Marijuana Smoking, Middle Aged, Psychotic Disorders, Risk Factors, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.